These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33617131)

  • 21. 2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network.
    Bettinger JA; De Serres G; Valiquette L; Vanderkooi OG; Kellner JD; Coleman BL; Top KA; Isenor JE; McCarthy AE;
    Euro Surveill; 2020 Jun; 25(22):. PubMed ID: 32524947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of telephone helpline data for syndromic surveillance of adverse events following immunization in Australia: A retrospective study, 2009 to 2017.
    Mesfin YM; Cheng AC; Enticott J; Lawrie J; Buttery JP
    Vaccine; 2020 Jul; 38(34):5525-5531. PubMed ID: 32593607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surveillance of adverse events following immunisation: Australia 2002 to 2003.
    Lawrence G; Boyd I; McIntyre P; Isaacs D
    Commun Dis Intell Q Rep; 2004; 28(3):324-38. PubMed ID: 15574056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful methodology for large-scale surveillance of severe events following influenza vaccination in Canada, 2011 and 2012.
    Bettinger JA; Rouleau I; Gariepy MC; Bowie WR; Valiquette L; Vanderkooi OG; Kellner JD; Coleman BL; McNeil SA; McCarthy A; De Serres G;
    Euro Surveill; 2015 Jul; 20(29):21189. PubMed ID: 26227369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced passive surveillance of influenza vaccination in England, 2016-2017- an observational study using an adverse events reporting card.
    de Lusignan S; Ferreira F; Damaso S; Byford R; Pathirannehelage S; Yeakey A; Yonova I; Schuind A; Dos Santos G
    Hum Vaccin Immunother; 2019; 15(5):1048-1059. PubMed ID: 30648923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project.
    Lee GM; Greene SK; Weintraub ES; Baggs J; Kulldorff M; Fireman BH; Baxter R; Jacobsen SJ; Irving S; Daley MF; Yin R; Naleway A; Nordin JD; Li L; McCarthy N; Vellozzi C; Destefano F; Lieu TA;
    Am J Prev Med; 2011 Aug; 41(2):121-8. PubMed ID: 21767718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis.
    Dos Santos G; Shende V; Damaso S; Yeakey A
    Adv Ther; 2019 Dec; 36(12):3340-3355. PubMed ID: 31595482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16.
    Bricout H; Chabanon AL; Souverain A; Sadorge C; Vesikari T; Caroe TD
    Euro Surveill; 2017 May; 22(18):. PubMed ID: 28494843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Active surveillance study of adverse events following immunisation of children in the Czech Republic.
    Danova J; Kocourkova A; Celko AM
    BMC Public Health; 2017 Feb; 17(1):167. PubMed ID: 28166783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NSW annual report describing adverse events following immunisation, 2010.
    Mahajan D; Campbell-Lloyd S; Cook J; Menzies RI
    N S W Public Health Bull; 2011 Nov; 22(9-10):196-208. PubMed ID: 22060057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England.
    de Lusignan S; Dos Santos G; Correa A; Haguinet F; Yonova I; Lair F; Byford R; Ferreira F; Stuttard K; Chan T
    BMJ Open; 2017 May; 7(5):e015469. PubMed ID: 28515198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parental views on vaccine safety and future vaccinations of children who experienced an adverse event following routine or seasonal influenza vaccination in 2010.
    Parrella A; Gold M; Marshall H; Braunack-Mayer A; Watson M; Baghurst P
    Hum Vaccin Immunother; 2012 May; 8(5):662-7. PubMed ID: 22634441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early signal detection of adverse events following influenza vaccination using proportional reporting ratio, Victoria, Australia.
    Clothier HJ; Lawrie J; Russell MA; Kelly H; Buttery JP
    PLoS One; 2019; 14(11):e0224702. PubMed ID: 31675362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surveillance of adverse events following immunisation: Australia, 2000-2002.
    Lawrence G; Menzies R; Burgess M; McIntyre P; Wood N; Boyd I; Purcell P; Isaacs D
    Commun Dis Intell Q Rep; 2003; 27(3):307-23. PubMed ID: 14510057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season.
    Dos Santos G; Nguyen BY; Damaso S; Godderis L; Martínez-Gómez X; Eckermann T; Loos H; Salamanca de la Cueva I; Shende V; Schmidt AC; Yeakey A
    Drug Saf; 2020 Mar; 43(3):265-279. PubMed ID: 31884676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
    Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M
    Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study.
    Daley MF; Clarke CL; Glanz JM; Xu S; Hambidge SJ; Donahue JG; Nordin JD; Klein NP; Jacobsen SJ; Naleway AL; Jackson ML; Lee G; Duffy J; Weintraub E
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):59-68. PubMed ID: 29148124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Active surveillance for safety monitoring of seasonal influenza vaccines in Italy, 2015/2016 season.
    Spila Alegiani S; Alfonsi V; Appelgren EC; Ferrara L; Gallo T; Alicino C; Pascucci MG; Aquilani S; Spadea A; Tafuri S; Rizzo C
    BMC Public Health; 2018 Dec; 18(1):1401. PubMed ID: 30577729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of seizures among adults and children following influenza vaccination using health insurance claims data.
    Thyagarajan V; Su S; Gee J; Duffy J; McCarthy NL; Chan KA; Weintraub ES; Lin ND
    Vaccine; 2013 Dec; 31(50):5997-6002. PubMed ID: 24148576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Participant centred safety surveillance of health care workers receiving influenza vaccination.
    Cashman P; Moberley S; Chee K; Stephenson J; Chaverot S; Martinelli J; Gadsden T; Bateman-Steel C; Redwood L; Howard Z; Ferson MJ; Durrheim DN
    Vaccine; 2019 Apr; 37(18):2427-2429. PubMed ID: 30930006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.